Study Result Disclosure Treated As Carefully As FDA Submissions – PhRMA
Executive Summary
Drug companies are approaching their clinical trial results disclosures with the same degree of attention as FDA submissions, Pharmaceutical Research & Manufacturers of America VP-Scientific & Regulatory Affairs Caroline Loew said